Boston Scientific Corporation $BSX Shares Bought by ZWJ Investment Counsel Inc.

Key Points

• ZWJ Investment Counsel increased its Boston Scientific stake by 25.3% in the third quarter, acquiring 149,431 additional shares and bringing its holdings to 739,647 shares valued at approximately $32.3 million.
• Institutional ownership remains high at 89.07%, while company insiders purchased roughly $9.4 million in shares over the past three months, including significant purchases by the CEO and a director.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $68.23. Boston Scientific recently exceeded quarterly EPS and revenue estimates, reporting $0.86 EPS on $5.44 billion in revenue, with revenue up 7.5% year over year.

ZWJ Investment Counsel Inc. increased its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 25.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 739,647 shares of the medical equipment provider's stock after acquiring an additional 149,431 shares during the period. ZWJ Investment Counsel Inc. owned approximately 0.05% of Boston Scientific worth $32,286,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in BSX. Mather Group LLC. lifted its position in Boston Scientific by 74.7% in the third quarter. Mather Group LLC. now owns 18,131 shares of the medical equipment provider's stock worth $831,000 after purchasing an additional 7,750 shares during the period. MinichMacGregor Wealth Management LLC bought a new position in Boston Scientific during the 3rd quarter valued at $201,000. First Citizens Bank & Trust Co. acquired a new position in shares of Boston Scientific during the 3rd quarter valued at $1,268,000. Focus Financial Network Inc. increased its position in shares of Boston Scientific by 16.1% during the 3rd quarter. Focus Financial Network Inc. now owns 43,182 shares of the medical equipment provider's stock valued at $2,066,000 after purchasing an additional 5,979 shares during the period. Finally, Q Fund Management Hong Kong Ltd acquired a new position in shares of Boston Scientific during the 3rd quarter valued at $426,000. 89.07% of the stock is currently owned by institutional investors.

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney purchased 186,240 shares of the firm's stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares of the company's stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Edward J. Ludwig purchased 5,000 shares of the company's stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 194,522 shares of company stock valued at $9,385,210 over the last three months. Company insiders own 0.34% of the company's stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of several research reports. Robert W. Baird set a $56.00 target price on Boston Scientific in a research note on Thursday, July 30th. Canaccord Genuity Group lowered their target price on Boston Scientific from $70.00 to $66.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. Stifel Nicolaus set a $60.00 price target on shares of Boston Scientific in a research report on Wednesday, July 29th. Wells Fargo & Company cut their price target on shares of Boston Scientific from $50.00 to $48.00 and set an "equal weight" rating for the company in a report on Wednesday, September 23rd. Finally, Piper Sandler cut their price target on shares of Boston Scientific from $65.00 to $60.00 in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of "Moderate Buy" and a consensus price target of $68.23.

Boston Scientific Price Performance

NYSE BSX opened at $43.03 on Thursday. The stock has a market capitalization of $62.36 billion, a P/E ratio of 17.42, a P/E/G ratio of 1.04 and a beta of 0.58. Boston Scientific Corporation has a 1 year low of $41.38 and a 1 year high of $105.65. The business's fifty day moving average is $46.26 and its two-hundred day moving average is $49.97. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The company's quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 3.25 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company's portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.